BioNotebook: Juno's $134m Series B more than 3 VC deals combined

Juno Therapeutics continues to astound the biotechnology industry and the 2013 startup hasn't even reported any human clinical trial results, but the Seattle, Washington-based company has raised an eye-popping $310m in venture capital financing since its launch in December.